版本:
中国

BRIEF-Cara Therapeutics starts enrollment in phase 2B trial of oral CR845

Sept 15 Cara Therapeutics Inc :

* Cara Therapeutics initiates enrollment in phase 2B trial of peripherally acting kappa opioid agonist, oral CR845, in chronic pain patients

* Says expects to report top-line data from this trial during first half of 2017

* Says trial to evaluate three tablet strengths of CR845 versus placebo in approximately 330 osteoarthritis patients Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐